Document Detail


Intravenous MgSO4 alone and in combination with glucose, insulin and potassium (GIK) prolong the atrial cycle length in chronic atrial fibrillation.
MedLine Citation:
PMID:  11225936     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: To investigate the effects of parenteral administration of MgSO4, and glucose, insulin, and potassium (GIK), on the dominant atrial cycle length during chronic atrial fibrillation (CAF). METHODS AND RESULTS: The length of the dominant atrial cycle (DACL) in the power-frequency spectrum of the QRST-suppressed lead V1 ECG was identified before and after intravenous administration of MgSO4 alone and after 5 and 10 h of MgSO4 and GIK infusion, in 13 patients with CAF. The changes in DACL were compared with changes in heart rate (HR), blood pressure and blood parameters. MgSO4 alone increased the DACL from 146(13) (mean(SD)) (control) to 153(14) ms (P < 0.01) and decreased the HR from 102(22) to 95(18) beats x min(-1) (P < 0.05). After 5 h of MgSO4 and GIK infusion the DACL was increased compared with control, from 146(13) to 152(11) ms (P < 0.01), but unchanged compared with that after the bolus infusion of MgSO4. HR was decreased compared with control (102(22)) and the bolus infusion of MgSO4 (95(18)) to 87(15) beats x min(-1) after 5 h of intervention. The DACL was further increased after 10 h of MgSO4 and GIK infusion compared with both control (from 146(13) to 157(11) ms), (P < 0.01) and the 5h infusion (152(11) to 157(11) ms), (P < 0.05). No further changes were seen in HR after 10 h (87(17)) of intervention. There were indications of an inverse relationship between total changes in HR (deltaHR) and DACL (deltaDACL) during the interventions (P < 0.05). CONCLUSION: Bolus infusion of MgSO4 prolongs the DACL and decreases HR in CAF. A further prolongation of DACL was seen after 10 h of MgSO4 and GIK infusion compared with control and with 5 h of intervention. Changes in DACL and HR during the entire intervention period showed an inverse relationship. The antiarrhythmic properties of MgSO4 and the GIK solution in CAF clearly require further attention.
Authors:
M P Ingemansson; B Smideberg; S B Olsson
Related Documents :
2978996 - Atrial natriuretic factor: physiologic actions and implications in congestive heart fai...
19783776 - Role of nitric oxide as a key mediator on cardiovascular actions of atrial natriuretic ...
11018206 - Effect of degree of blood pressure on the hypercoagulable state in chronic atrial fibri...
2940116 - Atrial natriuretic factor: an overview.
3793286 - The relationship of salt intake and arterial blood pressure in salted-tea drinking kash...
9369286 - Relationship of tachycardia with high blood pressure and metabolic abnormalities: a stu...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology     Volume:  2     ISSN:  1099-5129     ISO Abbreviation:  Europace     Publication Date:  2000 Apr 
Date Detail:
Created Date:  2001-02-27     Completed Date:  2001-04-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100883649     Medline TA:  Europace     Country:  England    
Other Details:
Languages:  eng     Pagination:  106-14     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Lund University, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anti-Arrhythmia Agents / administration & dosage*
Atrial Fibrillation / drug therapy*,  physiopathology*
Cardioplegic Solutions / administration & dosage*
Chronic Disease
Drug Therapy, Combination
Electrocardiography / drug effects
Female
Glucose / administration & dosage*
Humans
Infusions, Intravenous
Insulin / administration & dosage*
Magnesium Sulfate / administration & dosage*
Male
Middle Aged
Potassium / administration & dosage*
Time Factors
Chemical
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Cardioplegic Solutions; 0/glucose-insulin-potassium cardioplegic solution; 11061-68-0/Insulin; 50-99-7/Glucose; 7440-09-7/Potassium; 7487-88-9/Magnesium Sulfate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effective treatment for mental disorders in children and adolescents.
Next Document:  Stroke prevention practices in patients with atrial fibrillation and pacemaker therapy: evidence for...